Patent · US Active

Anti-XDR-TB drug, anti-MDR-TB drug, and combination anti-tuberculosis drug

US9040502B2 · kind B2 · utility

0Cited by
2References
3Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 30, 2011
Grant dateMay 26, 2015
Priority date
Expiry dateFeb 6, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.